Objective. Advanced complex regional pain syndrome (CRPS) remains very difficult to treat. While subanesthetic low-dose ketamine has shown promise in early localized CRPS, its use in advanced CRPS has not been as effective. Since ketamine's analgesic potency and duration of effect in neuropathic pain are directly dose-dependant, we investigated the efficacy of ketamine in anesthetic dosage in refractory CRPS patients that had failed available standard therapies.
Introduction
T he understanding of the pathophysiology of mechanisms underlying complex regional pain syndrome (CRPS) has vastly progressed in the recent years [1] . Recent evidence has been presented that suggests focal small-fiber axonal degeneration and alteration of the cutaneous innervation by small-diameter afferent and postganglionic sympathetic efferent fibers are important for its induction and maintenance [2, 3] . Caveats of this hypothesiz have been raised by Janig and Baron [4] , who propose that patients with CRPS have concomitant peripheral changes in the microenvironment at the site of injury that induce peripheral afferent sensitization, neurogenic inflammation, and sympathetic afferent coupling in addition to functional reorganization of the somatosensory, motor, and autonomic circuits in the central nervous system (CNS) [5] [6] [7] .
There is general agreement that the pain in CRPS is disproportionate to the extent of the primary triggering injury that does not respect a root or nerve territory. Characteristic symptoms include severe unrelenting burning and deep pain, associated with mechano-and thermal allodynia, hyperalgesia, and hyperpathia. Swelling, autonomic dysregulation, a movement disorder, atrophy, and dystrophy are associated to varying degrees [8] . The syndrome may progress with time, and signs and symptoms may spread to sites that were not primarily affected. In some patients, it is generalized [9, 10] . Current standard therapy consists of a variety physical, psychological, behavioral, pharmacological and interventional treatments [11] [12] [13] . Unfortunately, a subgroup of CRPS patients remains refractory to all standard therapy. For these refractory patients, no effective treatment exists [8] .
Ketamine, the currently most potent clinically available N-methyl-D-aspartate (NMDA)-antagonist, has a well-established role in the treatment of acute and chronic pain [14, 15] . Its main action is through inhibition of NMDAreceptors, which are thought to play a crucial role in the generation and maintenance of chronic pain [16, 17] . In addition to its acute analgesic effects, systemic ketamine modulates correlates of central sensitization in chronic pain states on a long-term basis. Wind-up and punctuate hyperalgesia were shown to be significantly reduced up to 7 days after surgery [18] . Ketamine administered at higher intraoperative dosage for major abdominal surgery reduced the area of wound hyperalgesia and significantly prevented the initiation and maintenance of chronic pain [19, 20] . Possible mechanisms are that these effects are mediated through NMDA-receptor inhibition, which may be critical for central sensitization, and anti-inflammatory modulation of the immune system [17, 21] . Proinflammatory cytokines are involved in the processes of peripheral and central sensitization and are inhibited by ketamine [22] . In the management of chronic pain, the use of ketamine at higher dosages has been limited by psychotropic side effects. The incidence and severity of ketamine side effects are dosedependent as are its analgesic potency and duration of action [15] .
Several series and case reports have documented reduction of pain intensity, allodynia and associated CRPS signs of autonomic dysregulation and motor dysfunction following the administration of subanesthetic systemic, epidural, and topical ketamine [23] [24] [25] [26] . A recent case report and larger series demonstrated long-term pain relief from subanesthetic ketamine infusions, particularly in early and well localized CRPS [27, 28] . However, in a subgroup of refractory CRPS with spreading disease, subanesthetic continuous S(+)-ketamine infusions were ineffective [29] .
This suggested that ketamine in anesthetic dosages might be effective in this refractory CRPS subgroup. Excellent clinical results were obtained with anesthetic doses of ketamine administered on a compassionate care basis to several refractory CRPS patients (unpublished). Based on this limited clinical experience, a standardized treatment regime was developed, and utilized in the present trial. The therapeutic efficacy of ketamine in anesthetic dosage was studied in a Phase II study in 20 refractory CRPS-patients, who suffered either longstanding or rapidly progressive disease that had failed standard therapy. The primary outcome parameter was acute and long-term relief of pain. Other measures included effects on the movement disorder, quality of life, social integration, and the ability to work at 6 months following treatment.
Methods

Patients
The human investigation committees in Tübingen and Saarbrücken, Germany, approved the study. Patients were recruited in the pain clinics of the Department of Neurology of Drexel University College of Medicine (Philadelphia, PA) and pain clinics of the Teaching Hospital University of the Saarland (Saarbrücken, Germany). Informed consent emphasized the experimental nature of this treatment. Special emphasis was placed on the risks associated with the intensive care component of this treatment which includes respiratory and urinary tract infections and other infectious complications such as systemic inflammatory response syndrome and sepsis. Organ failure (single or multi-organ failure), cardiovascular complications as well as the associated high morbidity and mortality rates of all of these serious complications were stressed. All patients gave their informed written consent.
Inclusion Criteria
All patients fulfilled the 1993 IASP-CRPS diagnostic criteria, the 1999 modified research diagnostic CRPS criteria, and the proposed modified research diagnostic criteria of the 2005 Budapest conference in at least one limb [30] [31] [32] . Other associated CRPS factors [1] [2] [3] [4] were noted to varying degrees in contiguous areas of the extremity, the face or in a mirror distribution. Cluster analysis placed all patients in subgroup; and [3] a florid CRPS syndrome [32] .
The average daily pain intensity had to be 7 points or greater on a numerical rating scale (Numeric Rating Scale [NRS] endpoints 0: no pain, 10: worse pain imaginable) over a period of at least 6 months while on standard therapy. The CRPS symptomatology had to be either longstanding and spreading, or rapidly progressive. Standard conventional nonmedical (physical therapy, psychological approaches), or pharmacological and interventional treatment modalities had to have failed. Failure of therapy was defined as: 1) no benefit from treatment, or 2) no lasting pain relief (>2 months). The designation "refractory" included documented failure of: 1) nonmedical; 2) pharmacological mono-, or combined therapy with nonsteroidal antiinflammatory drugs, tricyclic antidepressants, anticonvulsants, low or high potency opioids; 3) at least three interventional procedures, including selective nerve blocks, epidural analgesia, brachial plexus blocks, sympathetic ganglion blocks, intravenous regional sympathetic blocks, spinal cord stimulation, surgical sympathectomy, or intrathecal drug delivery systems; and 4) unchanged or progressing state of disease despite these efforts.
Inclusion was limited to ASA I-III patients (ASA: American Society of Anesthesiologists Physical Status Classification), which apart from their pain-related disability, did not suffer from clinically relevant systemic disease. Patients that presented with a history of significant cardiovascular, pulmonary, renal disease or mental disorders were excluded. Further exclusion criteria included known contraindications to ketamine use (severe arterial hypertension, hyperthyroidism, ischemic heart disease or heart failure), as well as allergies to ketamine or midazolam. All patients during the course of their treatments were evaluated by a psychiatrist for counseling and support and 9 underwent detailed neuropsychological testing prior to and following treatment [33] . All patients had difficulty falling and staying asleep but this feature of their illness was not studied systematically. Patients with a history of substance or drug abuse, or a suspected somatoform pain disorder were excluded. The inclusion criteria were evaluated by three physicians, a neurologist (RJS), and two anesthesiologists (RTK, PR).
Ketamine Treatment Protocol
Anesthesia was induced by bolus injection of ketamine (1-1.5 mg/kg) and midazolam (2.5-7.5 mg). Tracheal intubation was facilitated by vecuronium (0.1 mg/kg). Treatment was maintained by infusions of ketamine over 5 days, starting at 3 mg/ kg/h, followed by gradual daily titration up to a final dose of 7 mg/kg/h. Midazolam was co-administered and adjusted as clinically required (0.15-0.4 mg/kg/h) to obtain a stable level of deep sedation (Ramsay-Score 4-5), and to attenuate ketamine-specific side effects, i.e., agitation [34] . The first three patients were not intubated and spontaneous ventilation was allowed. The remaining 17 patients were electively intubated, to limit the risk of aspiration. These 17 patients were mechanically ventilated. After 5 days, infusions were slowly tapered, first by reducing the ketamine dosage by 20% every four hours, followed by gradual reduction of midazolam in the same manner. Patients were then weaned from mechanical ventilation and extubated once adequate spontaneous ventilation, sufficient gas exchange, and the appropriate level of consciousness together with intact protective reflexes was attained.
Ketamine and Norketamine Plasma Concentrations
Blood samples were drawn into prefabricated EDTA-tubes (S-Monovette ® , Sarstedt AG & Co., Nürnbrecht, Germany) from all patients every eight hours to determine ketamine and norketamine (the primary ketamine metabolite) plasma concentrations during anesthesia and for 3 days following treatment. Blood samples were centrifuged and plasma aliquots stored until analysis at -80°C. Ketamine and norketamine plasma concentrations were analyzed by simultaneous highpressure liquid chromatography (HPLC) [35] .
Standardized Additional Drugs
Deep Venous Thrombosis and Ulcer Prophylaxis All patients received intravenous unfractionated low-dose heparin 7.500-15.000 I.E./day (Liquemin ® , Roche, Germany) under regular aPTT monitoring, and the proton pump inhibitor pantoprazole 40 mg/day (Pantozol ® , Altana Pharma, Germany).
Clonidine Clonidine (Catapresan ® , Boehringer Ingelheim, Germany) was administered intravenously (0.20-0.85 mg/kg/h) to control cardiovascular stimulation and the psychomimetic and potential neurotoxic side effects of ketamine. It was dosed as clinically required (0.20-0.85 mg/kg/h) to control tachycardia and hypertension. The coadministration of clonidine at a minimum dose of 0.15 mg/ kg/h was maintained throughout the intensive care treatment.
Alimentation and Glycemic Control Alimentation
The first three unintubated patients received full parenteral nutrition (25 kcal/kg/day) with a ternary mixture of aminoacids (40 g/L), glucose (160 g/L), and fat (40 g/L), containing 1040 kcal/L glucose-fat calories (Oliclinomel 
Glycemic Control
Intensified insulin-therapy (Actrapid ® , Novo Nordisk A/S, Denmark) was applied, and insulin dosed as clinically needed to maintain normoglycemia (blood glucose concentrations: 90-150 mg/ dL) [36] .
Patient Safety
Monitoring Continuous standard intensive care monitoring (arterial blood pressure monitoring, ECG and ST-segment analysis, core temperature, pulse oximetry, capnometry, central venous pressure) was performed in all patients. All patients had bladder catheterization.
Blood Gas Analysis and Blood Chemistry
Blood gas analysis was routinely performed every 8 hours and additionally when clinically warranted to adjust mechanical ventilation, insulin therapy, acid-base balance, and electrolytes. Detailed blood tests were performed before the treatment, daily during treatment, and for the first 2 weeks thereafter. Laboratory evaluation included cell counts, electrolytes, coagulation parameters, liver enzymes, C-reactive protein (CRP), creatine phosphokinase (CPK), and CKMB-isoenzyme activity.
Screening for Infectious Complications
When admitted patients were screened with pharyngeal, nose and rectal swabs for the presence of multiresistant pathogens (methycillin resistant S. aureus [MRSA]; vancomycin resistant enterococci [VRE] ). During the treatment screening included continuous monitoring of core body temperature, and laboratory parameters (daily leukocyte count, CRP), urine status, and tracheal secretion and urine cultures on the first day of treatment and when respiratory or urinary tract infection was suspected clinically. In the presence of fever blood cultures were collected.
Outcome Criteria
The patients' progress during the study, the times and nature of assessments at baseline, 1 week, 1, 3, and 6 months after treatment are summarized in a flow chart shown in Figure 1 .
Pain Assessment and Degree of Pain Relief
The degree of a patient's subjective pain intensities was rated by a numeric scale (NRS, endpoints: 0-no pain, 10-worst pain imaginable) at baseline and at follow-up examinations. The degree of pain relief following treatment was calculated as: percent pain relief = (NRS baseline -NRS follow up )/ NRS baseline ¥ 100.
Movement Disorder
Data were obtained at baseline and 1, 3, and 6 months after treatment for both upper and lower extremities.
Upper Extremity Motor Evaluation
Assessment of active range of motion was based on norms described by Kendall et al. [37] . Arm movement was quantified by utilizing a combination of the performance of specific motor tasks (placing a book in a shelf above shoulder level, ability to comb one's hair, putting on a sweater, tying an apron) in addition to the results of the range of motion evaluation. Hand movement assessment combined grip function (gripping and holding a cup) and pinch grip ability (gripping, holding and use of a key, pencil and writing). Based on the observed range of movement combined with performance in the described functional tasks, the movement disorder was quantified utilizing a 4-point rating scale: 0: normal movement; 1: moderate disability (moderately reduced active range of motion, muscular strength, initiation, and completion of motor tasks); 2: severe disability (severely restricted active range of motion, weakness, poor initiation, and completion of motor tasks); 3: total disability (only residual movement, severe weakness, and inability to perform motor tasks).
Lower Extremity Motor Evaluation
The assessment of motor function of the lower extremity was based on the ability to walk and was scored on a 4-point rating scale: 0: normal movement (unimpaired walking); 1: moderate disability (inability to walk 500 meters); 2: severe disability (inability to walk 200 meters); 3: total disability (ability to walk <50 meters or inability to walk).
Quality of Life
The assessments to estimate disease-related impairments in activities of daily living, social integration, and the ability to work represent recognized aspects of quality of life. The assessments were performed at baseline and at 3, and 6 months following therapy.
Activities of Daily Living
Patients were asked to rate their performance of typical activities of daily living. The representative tasks of everyday life were based on selected key items contained in valid questionnaires, such as the West Haven-Yale Multidimensional Pain Inventory (WHYMPI) and the Stanford Health Assessment Questionnaire (HAQ) [38, 39] . Patients were instructed to rate their ability to independently perform the following tasks: self-care (preparing meals and eating [cutting food], drinking, dressing, washing, drying, and combing), and household activities (house cleaning, grocery shopping, washing dishes, and gardening). The degree of impairment was rated using a 4-point numeric scale: 0: no impairment (all tasks can be performed independently), 1: moderate impairment (tasks can be accomplished but with difficulty), 2: severe impairment (<50% of activities can be performed independently); 3: total impairment (majority of tasks cannot be performed; dependent on the help of others).
Social Integration
Patients were queried in regard to their ability to function socially and rated their overall impairment. Representative activities were chosen from the aforementioned validated questionnaires (WHYMPI, HAQ). Patients were asked to rate their ability to perform recreational activities (pursuing hobbies, playing sports, taking trips, seeing friends/relatives, reading, going out), cultural activities (attending concerts, movies, theatre). The degree of impairment was rated using a 4-point numeric rating scale: 0: no impairment, 1: moderate impairment (all activities can be performed, but with difficulty), 2: severe impairment (<50% of activities can be performed independently), 3: total impairment (majority of activities cannot be performed and the patient is dependent on the help of others).
Ability to Work
The ability to work was rated on a 4-point scale: 0: no impairment, 1: moderate impairment (able to work more than 4 h/day but less than 8 h/day), 2: severe disability (able to work up to 4 h/day), 3: total impairment (able to work only 2 h/day or totally unable to work).
Side Effects of Treatment
Ketamine-Specific Side Effects Psychotomimetic side effects: the occurrence, duration, and severity of ketamine-specific psychotomimetic side effects were documented following treatment. These included: anxiety, hallucinations, restlessness, difficulty in concentration, disruption of sleep, dizziness, dysphoria, euphoria, and disorientation.
Other Adverse Treatment Effects
These included all potential adverse effects associated with the intensive care nature of the treatment, such as respiratory, urinary tract or systemic infection, and cardiovascular and pulmonary complications. The occurrence of these complications, their treatment and resolution were documented. 
Statistics
Results
Patient Demographics
Twenty ASA-Class I-III patients were enrolled and completed the study (18 female and two male; mean age 30.4 Ϯ 10.4 years, range: 14-48 years). The mean duration of CRPS was 49.4 Ϯ 25.0 months (range: 6-84 months). All patients suffered from severe or spreading CRPS. Two had rapid contiguous spread affecting the entire extremity, two suffered from mirror spread, and 16 had generalized CRPS. All patients had been unresponsive to multiple conventional treatments and had failed standard pharmacological therapy and numerous invasive procedures (Tables 1-4) .
Pain Intensities and Pain relief Pain Intensities
Pain intensities were analyzed for the entire group, as well as for the subgroup of patients with recurring initiating or maintaining pain (nociceptive or neuropathic, but without associated CRPS signs or symptoms) and the subgroup with relapsing CRPS (neuropathic pain and associated CRPS signs and symptoms). At baseline, pain intensity of the entire group (N = 20), and of the subgroups with later recurring pain, and relapsing CRPS were NRS 8.9 Ϯ 0.3, 8.8 Ϯ 0.2, and 9.2 Ϯ 0.2 (mean Ϯ SD), respectively, and no statistically significant differences between the groups were detected. Following ketamine treatment, a significant reduction of pain intensity was observed at 1 week and 1 month for the entire group (NRS 0.5 Ϯ 0.8, and 0.6 Ϯ 1.0), and the subgroup with recurring pain (1.4 Ϯ 0.7, and 1.7 Ϯ 1.1, N = 7) (P < 0.001). At 3 months, pain intensity was significantly (P < 0.001) reduced compared with baseline in the entire group (NRS 0.9 Ϯ 1.6) and the subgroup with recurring pain (2.0 Ϯ 0.9, N = 4). Three patients had a CRPS relapse, but had significantly reduced pain compared with baseline (NRS 3.8 Ϯ 1.4, P < 0.004). Pain intensity at 6 months was significantly reduced for the entire group of patients (2.0 Ϯ 2.4, P < 0.001), the subgroups with recurring pain (3.6 Ϯ 2.0, P < 0.001, N = 6), and those with a CRPS relapse (4.6 Ϯ 1.1, P < 0.002, N = 4). The results are summarized in Figure 2 .
Pain Relief
The calculated percentage of pain relief was significant following ketamine treatment at 1 week (mean Ϯ SD: 94.5% Ϯ 8.9, and at 1, 3, and 6 months (93.5% Ϯ 11.1, 89.4% Ϯ 17.0, 79.3% Ϯ 25.3) in the entire group of patients (P < 0.001). Analyses for the subgroup with recurring pain showed significant pain relief at 1 week (84.4% Ϯ 8.22, N = 7, P < 0.001), and 1, 3, and 6 months (81.4% Ϯ 11.5, 77.8% Ϯ 10.1, and 64.32% Ϯ 23.8, N = 7, 4, and 6, P < 0.001 in all), respectively.
Pain relief in the subgroup of CRPS patient with relapse was maintained at 3, and 6 months (59% Ϯ 14.7, N = 3, P < 0.004, and 50.21% Ϯ 10.6, N = 4, P < 0.002). Figure 2 summarizes the results.
Movement Disorder Upper Extremity
For statistical analyses, the separately assessed scores the impairment of movement in the arm and hand of each side of the body was added to a total score for hands and arms. Thus, the minimal sum score was 0 (normal bilateral movement) and maximal 6 (total bilateral impairment). All patients (N = 20) showed impaired movement in the upper extremities.
At baseline a sum score of 3.2 Ϯ 1.2 (mean Ϯ SD) for movement in the arms, and 3.7 Ϯ 1.2 for movement in the hands was documented (N = 20). At 1, 3, and 6 months, a significant (P < 0.001) reduction of the sum score was noted for the movement impairment in the arms (1.4 Ϯ 0.83, 0.5 Ϯ 0.8, and 0.4 Ϯ 0.8), and hands (1.6 Ϯ 0.8, 0.5 Ϯ 0.9, and 0.5 Ϯ 0.8), respectively.
Lower Extremity
Statistical analyses of scores for decreased movement in the lower extremities were based on the direct scores of the aforementioned 4-point-based numeric rating scale. Of the entire group, only those with a movement disorder in the lower extremity were included for statistical analyses. At baseline, patients with movement disorder of the lower extremity (N = 15) had a score of 2.3 Ϯ 0.7 (mean Ϯ SD). Following treatment, their impairment was significantly reduced at 1, 3, and 6 months (1.3 Ϯ 0.9, 0.6 Ϯ 0.7, and 0.6 Ϯ 0.6; N = 15, P < 0.001). Figure 3 summarizes the results. The performed interventions, which had failed, are indicated by a number, indicating the frequency of failed interventions, or by a "+." Failure was defined as being without primary effect on pain, or no lasting effect (>2 months) on pain relief. IVRSB = intravenous regional sympathetic blockade.
Quality of Life Activities of Daily Living
At baseline, the ability to independently accomplish activities of daily living was rated as severely impaired by seven, and as totally impaired by 13 patients, with a mean score of 2.35 Ϯ 0.4 (mean Ϯ SD) for the entire group. At 3 months, the impairment was rated as severe by one, as moderate by 12, and as not impaired by seven patients, with a mean score of 0.7 Ϯ 0.6, and a significant difference compared with baseline (P < 0.001). At 6 months, there was a significant difference in the ability to perform activities of daily living compared with baseline. One patient rated total impairment, three severe impairment, six moderate impairment, and 10 patients no impairment for a mean score of 0.7 Ϯ 0.9 (P < 0.001). Results are shown in Figure 4 . , and 6 months following treatment and significant differences compared with baseline (*P < 0.001), and the results of the subgroup analyses for patients with recurring pain (N = 7 at 1 week, and 1 month, N = 4 at 3, and N = 6 at 6 months) and significant differences compared with baseline, as well as results for the subgroup with relapsing CRPS (N = 3 at 3 months, N = 4 at 6 months) and significant differences compared with baseline (+P < 0.004; #P < 0.0029). Part (B) summarizes the percentage of pain relief following the treatment. Data are presented as means Ϯ SD for the entire group and the subgroups with recurring pain, and relapsing pain, respectively. Significant degrees in the percentage of pain relief are indicated (*P < 0.001; +P < 0.004; #P < 0.002). NRS = Numeric Rating Scale; CRPS = complex regional pain syndrome. Upper extremity: data show the results of a sum-score (movement disability scores of both body sides were added, thus a minimal score of 0 (normal bilateral movement), and 6 (total impaired bilateral movement) for impairment of movement in arms and hands, and significant differences compared with baseline (*P < 0.001). (B) Lower extremity: results and significant differences in the movement disability score for the lower extremity at baseline and the follow up assessments (P < 0.001).
Social Integration
The impairment in social integration prior to treatment was rated as complete by 11 patients and severe by nine. Their mean impairment score was 2.5 Ϯ 0.5. At 3 months, their impairment was rated as severe by one, as moderate by 10, and nine were unimpaired. Their mean score of 0.6 Ϯ 0.6, was significantly improved compared with their pretreatment baseline (P < 0.001). At 6 months, there was significant improvement in the group with one patient rating total impairment, two severe impairment, six moderate impairment, and 11 patients no impairment (mean score of 0.6 Ϯ 0.8 (P < 0.001). Results are shown in Figure 4 .
Ability to Work
The impairment in the ability to work prior to treatment was rated as complete by 11, severe by 5, and as moderate by four patients (mean impairment score of 2.3 Ϯ 0.8). At 3 months, the impairment in ability to work was rated as complete and severe by one patient in each category, as moderate by eight, and as not impaired by 10 patients (mean score of 0.6 Ϯ 0.8), which was significantly improved compared with their baseline (P < 0.001). At 6 months, there was significant improvement in the ability to work as only two patients in the cohort were unable to work, four had moderate impairment, and 14 patients had no impairment (mean score of 0.5 Ϯ 0.9) (P < 0.001). Results are shown in Figure 4 and Table 5 .
Ketamine and Norketamine Plasma Concentrations
High-pressure liquid chromatography analysis of ketamine and norketamine plasma levels was in 18 patients. The sampling and analysis of two patients was incomplete, because of initial technical difficulties and therefore were not included in the analyses. Figure 5 summarizes the plasma concentrations for ketamine and norketamine.
Side Effects
Ketamine-Specific Side Effects
Psychotropic Ketamine Side Effects Psychotropic side effects that included anxiety, dysphoria, nightmares, and difficulties with sleep were observed in the majority of patients upon emergence from ketamine anesthesia. The intensity of these ketamine-specific side effects was Figure 4 The results for the assessments of quality of life: the impairment in activities of daily living, the impairment in social integration, and the ability to work. Patients rated their impairment on a 4-point rating scale (0: no impairment, 3: total impairment). Part (A) shows the absolute number (N) of patients in each category of impairment at baseline and the followups, and significant differences compared with baseline (*P < 0.001). (B) Severity of impairment: the impairment scores for the entire group for impairment of activities of daily living, social integration, and the ability to work at baseline, 3, and 6 months and significant differences compared with baseline (*P < 0.001). most severe in the initial days following emergence from anesthesia and resembled an acute withdrawal. These symptoms were successfully treated with small doses of clonidine and/or benzodiazepines. The psychotropic side effects faded within the first week following treatment in the majority of patients. However, five patients reported difficulties with sleeping and recurring nightmares for a month following treatment. Muscular weakness was reported in all patients for as long as 4-6 weeks following treatment.
Adverse Treatment Effects Infectious Complications
No major or life threatening complications were observed. The majority of complications were infections associated with the intensive care nature of treatment. Seven patients had respiratory infections, tracheobronchitis in five, and pneumonia in two patients. Fever was observed early (within 24-48 hours) following the initiation of anesthetic doses of ketamine, with concomitant leucocytosis (12,000-16,000/mL) and elevation of the CRP (6-25 mg/dL). Culture of tracheal secretions revealed S. aureus (methycillin sensible S. aureus, N = 6), Klebsiella pneumoniae (N = 2), and Proteus mirabilis (N = 1), as the pathogens in these cases. Lower urinary tract infections were seen in six patients, and urine cultures revealed enterococcus species (E. faecium, E. faecalis), and E. coli as the pathogens. These infectious complications were successfully treated with antibiogram-guided antibiotic therapy. 
Laboratory Evaluation
Discussion
This open-label study suggests an impressive effect of anesthetic ketamine in advanced and refractory CRPS patients. Pain scores were significantly improved and long-term complete pain relief was observed in 50% of patients. Patients that suffered recurring pain alone and recurring pain in conjunction with a CRPS relapse also maintained significant relief during the course of the study. In addition, there was significant improvement of the movement disorder, ability to perform activities of daily living, and the ability to work in concert with the decrement in pain. However, the dramatic nature of the intervention would be expected to cause a strong placebo response and the nonrandomized uncontrolled design of this study leave its results suggestive but unproven.
There are many possible mechanisms that underlie the marked and long-lasting effects of anesthetic ketamine in these severely affected CRPS patients. Because this is an open-label phase II study with lack of controls, the results may not be completely attributable to ketamine. Anesthetic doses of ketamine have not been studied in the therapy of chronic pain states. Existing evidence for the efficacy of ketamine in chronic pain disorders was obtained by utilizing low subanesthetic dose protocols primarily for neuropathic pain states other than CRPS. The first data on the beneficial effects of ketamine for CRPS were obtained from case reports and small case series [23] [24] [25] [26] 28] . In these studies, subanesthetic ketamine was administered via systemic, epidural or topical routes and provided dramatic relief from pain and associated CRPS symptoms in some patients. However, these studies differ in the routes of ketamine administration, dosage, treatment time, patient clinical profiles, and the duration of observation following treatment. The main limitations in determining the benefit of ketamine in these studies are sample size, lack of a control population and standardization of the treatment and measurement protocols. Long-term pain relief for 8 months was observed following a 10-day course of epidural ketamine (0.25 mg/kg/h) in a patient with lower extremity CRPS [23] . Harbut utilized continuous subanesthetic ketamine for 6 days in a patient that had suffered 9 years of CRPS and achieved pain relief for 5 months [28] . Recently, a larger-scale retrospective case series described long-term relief from pain following continuous low-dose ketamine [27] . In this series, the best response to ketamine was observed in patients with early CRPS whose symptoms and signs were well localized to the distal aspects of one extremity. In a subgroup of refractory CRPS patients, we recently showed subanesthetic continuous S(+)-ketamine (500 mg/day) administered over 10 days (exceeding the equianalgesic ketamine dosages used by Correll) was ineffective in relieving pain or attenuating severe thermal and mechanical allodynia [29] . To our knowledge, there are no randomized controlled trials on the efficacy of ketamine in the treatment of CRPS.
Complex regional pain syndrome is generally thought to be a subset of neuropathic pain [2, 4] . Although as noted above, inflammatory components are often predominant in early stages [40, 41] , the exact pathophysiology is unknown but strides have been made in the understanding of possible mechanisms that underlie the generation and maintenance of this possible neuropathic pain [8, 17] . A critical role for NMDA-receptors that contribute to central sensitization in chronic neuropathic pain is well established [16, 17] . Consequently, the efficacy of several NMDA-receptor antagonists has been investigated in various neuropathic pain conditions. In human and animal studies, ketamine was shown to have a dosedependent effect on neuropathic pain features, such as secondary hyperalgesia, allodynia, longterm potentiation, and wind-up [42] [43] [44] [45] [46] . Several clinical trials in neuropathic pain conditions have confirmed beneficial effects of ketamine in the therapy of chronic pain. In a randomized controlled trial of postherpetic neuralgia, iv ketamine significantly reduced pain, allodynia, and hyperpathia [47] . Similarly, intravenous ketamine has been shown to produce significant pain relief and reduction of wind-up pain in a randomized controlled trial of chronic phantom pain [48] . A randomized trial of intramuscular ketamine provided 24 hours of significant pain relief in patients with facial neuralgia [49] . Several trials have noted longterm affects of ketamine that outlast its pharmacological profile [18] [19] [20] 49] . In addition, animal and clinical studies have demonstrated that the efficacy of ketamine is dose-dependent [19, 43, 44, 50] . As the incidence and degree of ketamine side effects also depends on dosage, most trials in pain medicine have been performed with low doses [14] . This trial of anesthetic dosage of ketamine in refractory CRPS, as well as the first patient treated on a compassionate care basis [51] demonstrated longterm significant pain relief that outlasts its pharmacological profile.
Many aspects of the pathophysiology of CRPS remain unclear. Recently, CRPS has been posited to be a disease of the CNS [7] . The molecular mechanisms underlying CRPS are hindered by lack of an exact animal model that is completely valid for this complex clinical entity [52] . Its characteristic signs and symptoms may occur as a consequence of dysregulated efferent central control of several systems (i.e., somatosensory, motor, and sympathetic) and appears to be maintained from a peripheral sensitizing afferent nociceptive barrage. The molecular mechanisms responsible for inducing and maintaining these lasting and selfmaintaining neuroplastic changes in CRPS are not known but there is evidence for NMDA-receptor mediated neuronal plasticity and facilitation of central pain processing [8] . Another potential mechanism underlying the syndrome is injury induced activation of central microglia that secrete inflammatory cytokines which activate central pain projecting neurons [53] . The relative importance of mechanisms for central sensitization mediated by the NMDA-receptor and subsequent calcium cascades or effects of inflammatory cytokines on pain transmission neurons or both in concert is not known [17, 21] . Recent evidence in a rat model of neuropathic pain demonstrated a comparable long-term suppression of allodynia by ketamine that outlasted the duration of its NMDA blockade [50] . Thus, down-regulation of central sensitization mediated by NMDA-receptor blockade might explain in part long-term effects of ketamine in neuropathic pain.
Other relevant mechanisms mediated by ketamine that contribute to pain relief in these patients must be considered. These include potential modulation of peripheral NMDA-and non-NMDA-receptors. Ketamine inhibits peripheral glutamate receptors which play a role in both peripheral and subsequent central sensitization [54] . In addition, ketamine interacts with various receptors involved in nociception that include AMPA and kainate glutamate receptors, voltagedependent ion channels, sodium and L-type calcium channels, opioid receptors (m-, k-, and d-opioid receptors), GABA A -receptors, and nicotinic and muscarinic acetylcholine receptors [15] . Ketamine induced inhibition of nitric-oxide synthase might also contribute to its analgesic effects [15] . As noted above, proinflammatory mediators are known to play an essential role in the processes of peripheral and central sensitization [55] . Ketamine induces a profound inhibition of proinflammatory cytokines and other inflammatory mediators, both in experimental and clinical studies [15, 22] . A recent study demonstrated significant increases in proinflammatory cytokines in the cerebrospinal fluid of CRPS patients, which suggests a potential role of neuroimmune activation in CRPS [56] . The anti-inflammatory effects of ketamine administered in anesthetic doses may also play a role in its effects on these patients. Alternatively or in addition to ketamine, midazolam and clonidine may also contribute to the effectiveness of this treatment. Clonidine, a central a 2 -adrenergic agonist, has analgesic properties [57] . Its analgesic potency is weak but has effect when administered by epidural, intrathecal or a transdermal route. Although the analgesic effects of intravenous clonidine are controversial, a synergistic interaction with ketamine in our patients is possible [57] . Another synergistic effect of this treatment may be due to midazolam, a short-acting GABA A agonist. In the course of central sensitization, GABA-ergic inhibitory transmission is depressed by NMDA-dependent mechanisms which leads to prolonged depression of inhibitory transmission and thus potentiation of central pain projecting neuron hyperexcitability [17, 58] . The large doses of midazolam administered during treatment would be expected to enhance GABA-ergic induced inhibition during this treatment while its role as an analgesic is unclear [17, 58] . The possible contributions of the placebo effect and or resetting of pain processing mechanisms due to 5 days of anesthesia in the beneficial effects of this treatment are unknown.
A most relevant concern of this invasive procedure is patient safety. Modern intensive care medicine standards achieve a high level of patient safety. Ketamine has been safely used for over 30 years in clinical anesthesia and also in intensive care. However, a potential concern is NMDARantagonist induced neurotoxicity that has been demonstrated in animal experimental work in the developing and adult rat brain [59] . Neurotoxic effects are prevented by administration of clonidine and GABA A -agonists [60, 61] . To the best of our knowledge, neurotoxicity of ketamine to date has not been demonstrated in humans [62] . Initial studies investigating ketamine sedation in brain injured patients in the intensive care setting were not associated with significant morbidity or mortality [63, 64] . However, these studies were not powered for a valid assessment of safety. The reported duration of ketamine sedation (6.1 Ϯ 3.2 days) and the dosage of ketamine (maximal dose: 94 Ϯ 23 mg/kg/min) are comparable to our study (5 days of sedation; maximal dose:~84 mg/kg/min) [63] .
Nonetheless, it must be emphasized that this protocol is associated with serious risks. The major complications observed in this study were respiratory and urinary tract infections, representing typical infections in intensive care. Although, in this series, infections resolved under antibiotic treatment, it must be emphasized that infectious complications still represent the main source of morbidity and mortality in modern intensive care medicine. Transient ketamine-specific psychotropic side effects occurred on emergence from ketamine anesthesia and were successfully controlled by benzodiazepines and clonidine. There were no long-term psychiatric or cognitive impairments in any patient [65] . Moderate muscle weakness persisted for a month to 6 weeks.
In addition to all of the limitations inherent in a nonrandomized uncontrolled trial, there are several other limitations of this study: 1) the movement disorder, social integration, activities of daily living and ability to work measures were subjective and have not been validated in CRPS patient; 2) the CRPS patient population studied is not representative of that seen in most pain centers as it is drawn from the entire USA; 3) the mechanism of the spread of other validated factors of CRPS from the area of original injury is not known. The severity of this clinical component in these patients is unusual and may represent or be a consequence of the role of central glia pathophysiology in chronic pain states, central sensitization, functional reorganization of pain processing systems or dysfunction of descending pain control mechanisms. The area of primary CRPS may be maintaining a more generalized pain state.
A complete double blind placebo controlled randomized clinical trial would be logistically and ethically at least difficult, but its realization represents a major challenge of future work to possibly confirm the observed effect.
Conclusion
This phase II open-label study utilizing anesthetic doses of ketamine with midazolam and clonidine suggests possible effectiveness for severe CRPS patients that have failed all available standard therapies. A definitive, large multicenter randomized controlled trial is needed to confirm these results. 
